VIRTUAL GRAND ROUNDS: Long Acting Injectable Antipsychotics as a Patient Centered Choice
Presented by:
John Lauriello, M.D.
Daniel Lieberman Professor and Chair
Department of Psychiatry and Human Behavior
Senior Vice President of Behavioral Health
Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA
Wednesday, June 22nd, 2022
11:30 a.m. – 1:00 p.m.
Live Presentation via Zoom
Register Here: https://silverhill.zoom.us/webinar/register/WN_L_YAzTVcRkWZFi9BdABbrg
In this talk we will review currently used long acting injectable antipsychotics, their rationale for use, and patient and clinician attitudes about prescribing them. We will also discuss newer formulations and how they may or may not impact acceptance of this delivery method.
Educational Objectives
As a result of participating in this activity, learners should be able to:
- Discuss the reason why clinicians may or may not prescribe long acting injectable antipsychotics (LAIs)
- Review factors that affect patient’s willingness to take oral medications
- Describe the similarities and differences in the currently used LAIs
After registering, you will receive a confirmation email containing information about joining the Zoom webinar
Accreditation Statement: Silver Hill Hospital is accredited by the Massachusetts Medical Society to provide continuing medical education for physicians.
Designation Statement: Silver Hill Hospital designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This program has been approved for 1.5 Continuing Education Credit Hours by the National Association of Social Workers, CT and meets the continuing education criteria for CT Social Work Licensure renewal. Approval also meets the continuing education criteria for CT LMFTs, LPCs, and licensed psychologists
Dr. Lauriello’s Disclosures: Advisory Panel for Bioexcel Therapeutics and Orexo; Data Safety Board Bioexcel Therapeutics, Data Safety Board Avanair Pharmaceuticals, and Data Safety Board Karuna Therapeutics. All relevant financial relationships have been mitigated prior to the beginning of this activity in accordance with ACCME policies.
All planners have reported no relevant financial relationships with ineligible companies for this activity.